PT-141 (Bremelanotide) Protocol
Synthetic melanocortin receptor agonist (MC3R/MC4R) acting directly on central neural pathways to support libido, arousal, and vascular blood flow.
infoResearch & Clinical Context
Centrally-acting peptide investigated for sexual wellness and dopamine-mediated arousal pathways.
Mechanism & Biological Overview
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide analogue of alpha-MSH. Unlike traditional vascular agents that act solely downstream on blood vessels, PT-141 crosses the blood-brain barrier to bind hypothalamic melanocortin 4 receptors (MC4R), stimulating central dopamine release and neural arousal pathways in both men and women.
Key Biological Highlights & Benefits
- checkCentrally active mechanism operating via hypothalamic MC3R/MC4R receptors
- checkEnhances natural libido, arousal, and sexual responsiveness in men and women
- checkDoes not depend on direct vascular dilation or PDE5 inhibition
- checkSupports neurochemical dopamine signaling
Scientific Literature Abstract
"Bremelanotide operates as a non-selective melanocortin agonist with high affinity for MC3R and MC4R in the central nervous system. Activation of hypothalamic preoptic areas triggers downstream dopaminergic release, modulating autonomic sexual arousal independent of vascular endothelial smooth muscle tone."
hubTarget Receptor Pathways
Frequently Asked Questions
How does PT-141 differ from standard vascular agents?
PT-141 acts in the central nervous system (brain) to enhance desire and neurological arousal signaling, rather than acting purely as a peripheral vasodilator.
Can PT-141 be used by both men and women?
Yes, clinical research on MC4R melanocortin pathways includes both male and female sexual wellness protocols.
Explore Related Scientific Interventions
Semaglutide Protocol
A GLP-1 receptor agonist studied for appetite modulation and glycemic signaling pathways in metabolic health.
Tirzepatide Dual Agonist
Dual GIP and GLP-1 receptor agonist targeting complementary metabolic pathways for body composition and appetite research.
Retatrutide Triple Agonist
Triple receptor agonist (GIP, GLP-1, and Glucagon) studied for its potential effects on metabolic rate and lipid mobilization pathways.
Clinical & Legal Disclaimer
Medical Disclaimer: Information provided on this website is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Product availability, indications, regulatory status, and suitability may vary. Any medical treatment should be considered with an appropriately qualified healthcare professional.
NOVAMET does not guarantee specific weight-loss, metabolic, or treatment outcomes.